Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Current Deferred Revenue for 3 consecutive years, with $27.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 37.78% to $27.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.2 million, a 37.78% increase, with the full-year FY2025 number at $27.2 million, up 37.78% from a year prior.
  • Current Deferred Revenue was $27.2 million for Q4 2025 at Phathom Pharmaceuticals, up from $24.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $27.2 million in Q4 2025 to a low of $276000.0 in Q2 2023.
  • A 3-year average of $15.1 million and a median of $17.3 million in 2025 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 3490.58% in 2024, then increased 4.79% in 2025.
  • Phathom Pharmaceuticals' Current Deferred Revenue stood at $7.1 million in 2023, then surged by 178.12% to $19.8 million in 2024, then soared by 37.78% to $27.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Current Deferred Revenue are $27.2 million (Q4 2025), $24.3 million (Q3 2025), and $21.5 million (Q2 2025).